Anti-digoxin polyclonal antibody

Drug Profile

Anti-digoxin polyclonal antibody

Alternative Names: DIF; DigiBind; DigiFab; Digoxin Immune Fab; Digoxin Immune Fab (Ovine); Polyclonal antibody DigiTAb

Latest Information Update: 05 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glenveigh Pharmaceuticals; Protherics
  • Developer BTG; Velo Bio
  • Class Antidotes; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Poisoning
  • Phase II/III Preeclampsia

Most Recent Events

  • 01 Jun 2017 AMAG Pharmaceuticals announces intention to submit NDA to the US FDA for Preeclampsia in 2019, with an approval anticipated in 2020
  • 12 Apr 2017 Phase-II/III clinical trials in Preeclampsia in USA (IV)
  • 29 Dec 2016 Velo Bio plans a phase II trial for Preeclampsia in USA (IV, Infusion) (NCT03008616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top